8-K

                     SECURITIES AND EXCHANGE COMMISSION
                           WASHINGTON, D.C. 20549

                                  FORM 8-K
                               CURRENT REPORT

                   PURSUANT TO SECTION 13 OR 15(d) OF THE
                      SECURITIES EXCHANGE ACT OF 1934


                              January 31, 2001
                     ---------------------------------
                     (Date of earliest event reported)


                        DENDRITE INTERNATIONAL, INC.
           ------------------------------------------------------
           (Exact name of Registrant as specified in its charter)


  New Jersey                  0-26138                      22-2786386
- --------------         ---------------------           -------------------
(State of              (Commission File No.)              (IRS Employer
Incorporation)                                         Identification No.)


                          1200 Mount Kemble Avenue
                     Morristown, New Jersey 07960-6767
        ------------------------------------------------------------
        (Address of principal executive offices, including zip code)


                               (973) 425-1200
            ----------------------------------------------------
            (Registrant's telephone number, including area code)
                                     -


                               Not Applicable
       -------------------------------------------------------------
       (Former name or former address, if changed since last report)



Item 5.  Other Events.
         ------------

      Dendrite International, Inc. ("Dendrite") announced on January 31,
2001 that its Board of Directors has authorized a stock repurchase program
whereby Dendrite may purchase up to $20 million of its outstanding common
stock. Such purchases may be conducted in open market transactions or in
privately negotiated transactions from time to time. For information
regarding the stock repurchase program, reference is made to the press
release, dated January 31, 2001, of this announcement attached as Exhibit
99 to this Form 8-K.


Item 7.  Financial Statements and Exhibits.
         ---------------------------------

(c) Exhibits.

Exhibit No.       Exhibit
- -----------       -------
    99            Press Release, dated as of January 31, 2001, by Dendrite
                  International, Inc. concerning its stock repurchase
                  program





                                 SIGNATURES


            Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.


                              DENDRITE INTERNATIONAL, INC.


                              By: /s/ Christine A. Pellizzari
                                 ---------------------------------
                                 Name:    Christine A. Pellizzari
                                 Title:   Vice President, General
                                          Counsel and Secretary


Date: February 1, 2001






                             INDEX TO EXHIBITS



Exhibit No.    Exhibit
- -----------    -------
    99         Press Release, dated as of January 31,
               2001, by Dendrite International, Inc.
               concerning its stock repurchase program

EX-99

Dendrite International, Inc. Announces Stock Repurchase Program

MORRISTOWN, N.J.--(BUSINESS WIRE)--Jan. 31, 2001--Dendrite International,
Inc., the leading provider of sales and marketing effectiveness solutions
for the pharmaceutical industry (NASDAQ/NMS: DRTE - news), announced today
that its Board of Directors has authorized a stock repurchase program (the
"Repurchase Program ").

The Board of Directors authorized the repurchase of up to $20 million of
its out standing common stock over a two-year period.

The Company will repurchase shares on the open market or in privately
negotiated transactions from time to time. Repurchases of stock will be at
management's discretion, depending upon price and availability. The
repurchased shares will be held as treasury shares, which may be used to
satisfy Dendrite's current and near term requirements under its equity
incentive and other benefit plans and for other corpo rate purposes.
Dendrite currently has approximately 40 million shares of common stock
outstanding.

John Bailye Chairman and Chief Executive Officer of Dendrite International,
Inc. commented, "We believe that our stock presents a very attractive
investment opportunity for the Company at this time. The implementation of
the Repurchase Program serves to underscore our strong commitment to
enhance shareholder value."

ABOUT DENDRITE

Dendrite International, Inc. (NASDAQ/NMS:DRTE - news) designs and supports
technology-based knowledge systems that enhance the competitive activities
of the sales forces of the world's leading pharmaceutical companies.
Approximately one-third of all pharmaceutical sales representatives and
their managers worldwide rely on Dendrite.

www.dendrite.com

Note: Dendrite is a registered trademark of Dendrite International, Inc.

The foregoing contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. The statements may be
identified by such forward-looking terminology as "expect," "believe,"
"may," "will," "intend," "plan" and similar statements or variations. Such
forward-looking state ments are based on our current estimates and
assumptions and involve certain significant risks and uncertainties,
including: risks associated with and dependence on the pharmaceutical
industry; fluctuations in quarterly revenues due to lengthy selling cycles,
product implementation cycles, customer budget cycles, and timing of
revenue recognition; dependence on major customers; successful and timely
develop ment and introduction of new products and versions; rapid
technological changes; increased competition; retention of key senior
managers; and unique characteristics of the consumer packaged goods
industry. Other important factors, which should be considered, are included
in the Company's 10-K, 10-Qs and other reports filed with the SEC. Actual
results may differ materially. The Company assumes no obligation for
updating any such forward-looking statements.

Contact:

     Dendrite International, Inc.
     Brent Cosgrove, 973/425-1200